Gracell Biotechnologies PT Lowered to 11.00 at Citigroup
About 67% of Gracell Biotechnologies' investor base is looking to short. The analysis of current outlook of investing in Gracell Biotechnologies suggests that many traders are alarmed regarding Gracell Biotechnologies' prospects. Gracell Biotechnologies' investing sentiment shows overall attitude of investors towards Gracell Biotechnologies.
Gracell |
Gracell Biotechnologies had its price objective lowered by Citigroup from 12.00 to 11.00 in a research note issued to investors on Tuesday morning, Benzinga reports. The brokerage currently has a buy rating on the stock. Other equities research analysts also recently issued research reports about the stock. BTIG Research upped their
Read at thelincolnianonline.com
![]() |
Gracell Biotechnologies Fundamental Analysis
We analyze Gracell Biotechnologies' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gracell Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gracell Biotechnologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Short Ratio
Short Ratio Comparative Analysis
Gracell Biotechnologies is currently under evaluation in short ratio category among its peers. Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Gracell Biotechnologies Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Gracell Biotechnologies stock to make a market-neutral strategy. Peer analysis of Gracell Biotechnologies could also be used in its relative valuation, which is a method of valuing Gracell Biotechnologies by comparing valuation metrics with similar companies.
Peers
Gracell Biotechnologies Related Equities
CTMX | CytomX Therapeutics | 129.03 | ||||
ERAS | Erasca | 13.01 | ||||
CHRS | Coherus BioSciences | 5.15 | ||||
GLUE | Monte Rosa | 4.40 | ||||
DSGN | Design Therapeutics | 3.43 | ||||
BPMC | Blueprint Medicines | 3.23 | ||||
BOLT | Bolt Biotherapeutics | 2.78 | ||||
INZY | Inozyme Pharma | 2.61 | ||||
ASMB | Assembly Biosciences | 0.90 | ||||
AMLX | Amylyx Pharmaceuticals | 0.22 | ||||
TERN | Terns Pharmaceuticals | 0.66 | ||||
XFOR | X4 Pharmaceuticals | 0.89 | ||||
SPRO | Spero Therapeutics | 1.61 | ||||
ABOS | Acumen Pharmaceuticals | 2.00 | ||||
NXTC | NextCure | 4.44 | ||||
DAWN | Day One | 4.59 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in Gracell Stock
If you are still planning to invest in Gracell Biotechnologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gracell Biotechnologies' history and understand the potential risks before investing.
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |